The Patent Finder
US

Antibodies for Treatment of Cancer Expressing Claudin 6

US 10,233,253 In force
OverviewFamilyAssignmentsSources & methods

Term ends Apr 20, 2032 · Low confidence

Filed Mar 21, 2016 as application 15/076,536 · Granted Mar 19, 2019
Base term, 20 years from filing
Today
20 years from filing
2012 2032
Clock starts
Apr 20, 2012
Term ends
Apr 20, 2032
Granted
Mar 19, 2019
base term fee events Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 9,321,842, to Apr 20, 2032. The term already ends on or before that date, so the cap shortened nothing.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
6
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 2 of 3 maintenance fees are paid so far. Confidence: Low. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Apr 20, 2012, when application PCT/EP2012/001721, the earliest non-provisional in its chain, was filed (this one was filed Mar 21, 2016); a parent in its chain could not be resolved (the next row)Apr 20, 2032High confidence
Continuity chainA parent in the chain could not be resolveddated from this application's own claimMedium confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 9,321,842)resolves to Apr 20, 2032, no earlier than this term, so no changeHigh confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events2 of 3 maintenance fees paidIn forceHigh confidence
Further caveats on recordThe record names parents not resolved: 14117118Low confidence overallLow confidence
Computed term endThe steps above, in orderApr 20, 2032Low confidence

This family

US 9,321,842In force
Aug 2032
Aug 2032
US 10,233,253this patent
Apr 2032
Apr 2032
US 10,919,974In force
Apr 2032
Apr 2032
US 11,859,008In force
Apr 2032
Apr 2032
Application 18/520,264Pending
not computed
not computed
5 of 6 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Apr 4, 2017
Reel 42156, frame 574
Sahin, Ugur; Türeci, Özlem; Koslowski, Michael; Walter, Korden; Wöll, Stefan; Hubner, Bernd; Erdeljan, Michael; Weichel, Michael; Kreuzberg, MariaGanymed Pharmaceuticals AG; Johannes Gutenberg-Universität MainzAssignment of Assignor's Interest
Apr 4, 2017
reel/frame not recorded
Sahin, Ugur; Weichel, Michael; Hubner, Bernd; Koslowski, Michael; Erdeljan, Michael; Kreuzberg, Maria; Türeci, Özlem; Walter, Korden; Wöll, StefanGanymed Pharmaceuticals AGAssignment of Assignor's Interest
Apr 4, 2017
reel/frame not recorded
Sahin, Ugur; Weichel, Michael; Hubner, Bernd; Koslowski, Michael; Erdeljan, Michael; Kreuzberg, Maria; Türeci, Özlem; Walter, Korden; Wöll, StefanJohannes Gutenberg-Universität MainzAssignment of Assignor's Interest
Sep 29, 2017
Reel 44061, frame 844
Ganymed Pharmaceuticals AGGanymed Pharmaceuticals AGNotice of Change in Assignee Address
Jul 7, 2020
Reel 53135, frame 922
Ganymed Pharmaceuticals AGGanymed Pharmaceuticals GmbHChange of Name
Aug 4, 2025
Reel 71926, frame 811
Ganymed Pharmaceuticals GmbHAstellas Pharma Inc.Assignment of Assignor's Interest
Aug 4, 2025
Reel 72356, frame 929
Ganymed Pharmaceuticals AGGanymed Pharmaceuticals GmbHChange of Name
Nov 10, 2025
Reel 72847, frame 700
Johannes Gutenberg-Universität MainzTron - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg Universität Mainz GmbHAssignment of Assignor's Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited